Clinical research
Mid-February had a solid number of clinical trial announcements. Here’s a look.
The trial shows that the drug decreased the mortality rate of stroke from 19% to 11%.
Teva’s deutetrabenazine for the treatment of tics in pediatric patients with moderate to severe Tourette Syndrome did not meet the primary endpoint in the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
Recardio Inc., a clinical-stage life science company, announced that it has completed an interim analysis of its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction.
The Phase II trial did not meet its primary endpoint.
First-time results from recently completed fosciclopirox Phase I safety, dose tolerance, pharmacokinetics and pharmacodynamics trial in advanced solid-tumor patients
The trial evaluated INOpulse for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF).
It was a very busy week for clinical trial news. Here’s a look.
Now that global responses are fully mobilized, what is being done to identify and develop drugs and vaccines against this novel coronavirus?
PRESS RELEASES